High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients).
We evaluated the therapeutic outcomes of all antiretroviral-naive HIV-1-infected patients with fewer than 100 CD4 cells/microl, who received efavirenz-based highly active antiretroviral therapy (HAART). Sixty-one percent suffered AIDS-defining diseases, and after a median follow-up of 45 weeks there were three deaths and five AIDS-related conditions (two relapses, three new). Efavirenz-based HAART was found to be effective in profoundly immunosuppressed HIV-1-infected patients.
Arribas
Jose R
JR
Internal Medicine Service, La paz Hospital, Autónoma University School of Medicine, Madrid, Spain.
Pulido
Federico
F
Miró
Jose M
JM
Costa
María A
MA
González
Juan
J
Rubio
Rafael
R
Peña
Jose M
JM
Torralba
Miguel
M
Lonca
Montserrat
M
Lorenzo
Alicia
A
Del Palacio
Angel
A
Vázquez
Juan José
JJ
Gatell
Jose M
JM
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000821:virology; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology* / Q000401:mortality / Q000821:virology; D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D048588:Benzoxazines; D018791:CD4 Lymphocyte Count; D003521:Cyclopropanes; D005260:Female; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D010078:Oxazines / Q000627:therapeutic use*; D012008:Recurrence; D012189:Retrospective Studies
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; C098320:efavirenz